View our comprehensive portfolio of products for drug development and patient diagnosis and monitoring
Our products are trusted worldwide in research, clinical, and commercial laboratory settings.
Functional and biomarker assays for the exploration of every angle of the complement system
Our cell-based bioassays are based on iLite® technology – a cleverly designed cell-based assay system with reporter gene readouts
AAV Neutralizing Antibody (NAb), Total Antibody (TAb), and Complement Activation assays designed to provide a comprehensive view of vector immunogenicity
Solutions for detecting and semi-quantitating IgG antibodies against CCP
Our extensive CRO Services offer bioanalysis, biomarker discovery, and GMP QC testing.
With over 30 years of experience in autoimmune diagnostics, our ISO15189-certified specialist laboratory can help you reach the correct diagnosis. We also provide testing services and support for therapeutic drug monitoring.
Let us develop a custom iLite® cell line tailored to your needs.
Our cell services are highly reliable and innovative, tailored to your manufacturing needs
Watch Dr. Lubka Roumenina and her colleagues present their latest finding on the role of the complement system in renal cancer. They have recently published a paper in Cancer Immunology Research where they found that complement activation, as reflected by high plasma C4d or as C4d deposits at the tumor site, was associated with poor prognosis in patients suffering from renal cell carcinoma.
They also found that C1s, a C4-activating enzyme, plays a dual role in promoting ccRCC progression by triggering complement activation in a noncanonical manner.
Duration: ~17 minutes
Speaker: M. Revel, M. A. Dragon-Durey and L.T. Roumenina from Cordeliers Research Center INSERM, Paris.